The CD19 CAR-UiNK cell-treated mice survived significantly longer than the iNK cell-treated mice and the PBS-treated mice (Tumor + PBS: 19 days; Tumor + iNK: 20 days; Tumor + CD19 CAR-UiNK: 48 days; P < 0.001) (Figure 6D). This evidence concerns the gene CD19 and neoplasm.